Examination of glycobiomarker of the liver disease

Examination of glycobiomarker of the liver disease - Examination of glycobiomarker of the liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025644

Enrollment

120

Registered

2017-01-12

Start date

2016-09-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who performs a definitive NAFLD diagnosis by the liver biopsy in the patients that fatty liver was accepted by an examination of abdominal ultrasonic diagnosis

Exclusion criteria

Exclusion criteria: That merges hepatitis B, hepatitis C, cirrhosis, a hepatocellular carcinoma, autoimmune hepatitis, primary biliary cirrhosis

Design outcomes

Primary

Measure	Time frame
Glycobiomarkers with significant change in NASH and NAFL	—

Secondary

Measure	Time frame
Comparison with pathological findings by NAFLD Activity Score	—

Countries

Japan

Contacts

Public ContactKoji Ogawa

Hokkaido University Hospital Department of gastroenterology

k-ogawa@med.hokudai.ac.jp011-716-1161

Outcome results